Breaking News Instant updates and real-time market news.

ASNA

Ascena Retail

$2.73

-0.28 (-9.30%)

, ASPU

Aspen Group

$5.66

-0.14 (-2.41%)

18:59
12/10/18
12/10
18:59
12/10/18
18:59

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Ascena Rtail Group (ASNA) up 12.8%... Aspen Group (ASPU) up 3.9%. ALSO HIGHER: Cars.com (CARS) up 1.6% after receiving letter from Starboard urging potential break-up... Tronox (TROX) up 1.3% after disclosing purchase of stock by CEO... Crane (CR) up 0.9% after being initiated with a Buy at Buckingham. DOWN AFTER EARNINGS: Stitch Fix (SFIX) down 13.4%... Casey's General Stores (CASY) down 6.8%... Quanex Building Products (NX) down 6.8%. ALSO LOWER: CalAmp (CAMP) down 9.6% after lowering Q3 guidance... Ra Pharma (RARX) down 3.5% after equity offering... SAExploration Holdings (SAEX) down 1.5% after selling stock for holders.

ASNA

Ascena Retail

$2.73

-0.28 (-9.30%)

ASPU

Aspen Group

$5.66

-0.14 (-2.41%)

CARS

Cars.com

$23.94

-0.37 (-1.52%)

TROX

Tronox

$7.05

-0.25 (-3.42%)

CR

Crane

$78.23

-0.99 (-1.25%)

SFIX

Stitch Fix

$25.92

-0.42 (-1.59%)

CASY

Casey's General Stores

$119.64

-1.78 (-1.47%)

NX

Quanex

$14.05

-0.13 (-0.92%)

CAMP

CalAmp

$17.02

-0.23 (-1.33%)

RARX

RA Pharmaceuticals

$17.58

1.13 (6.87%)

SAEX

SAExploration

$3.33

-0.11 (-3.20%)

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 19

    Dec

  • 12

    Dec

ASNA Ascena Retail
$2.73

-0.28 (-9.30%)

06/05/18
RILY
06/05/18
NO CHANGE
Target $3.5
RILY
Neutral
Ascena Retail price target raised to $3.50 from $2.50 at B. Riley FBR
B. Riley FBR analyst Susan Anderson raised her price target for Ascena Retail Group to $3.50 saying same-store-sales improvement drove earnings to the high end of guidance in Q3. The analyst keeps a Neutral rating on the shares.
ASPU Aspen Group
$5.66

-0.14 (-2.41%)

02/12/18
CHLM
02/12/18
INITIATION
Target $12
CHLM
Buy
Aspen Group initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Mike Malouf started Aspen Group with a Buy rating and $12 price target saying the company is an online for-profit education institute that is establishing itself as a student-friendly disruptor to an industry rife with reputational issues.
02/12/18
02/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. First Solar (FSLR) initiated with an Underperform at Credit Suisse. The firm also started SunPower (SPWR) with a Neutral and Sunrun (RUN) with an Outperform. 2. Genocea (GNCA) initiated with an Outperform at Baird. 3. Tetraphase (TTPH) initiated with a Buy at B. Riley FBR. 4. Aspen Group (ASPU) initiated with a Buy at Craig-Hallum. 5. Vermilion Energy (VET) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/18
LSCM
07/13/18
NO CHANGE
Target $10
LSCM
Buy
Aspen Group sales outlook lowered on registration cap at Lake Street
Lake Street analyst Eric Martinuzzi lowered his fiscal 2019 revenue estimate for Aspen Group to $6.5M from $8.7M with the company needing to gain approval from the from the California Board of Registered Nursing in order to enroll more than 75 students every other month. The analyst, however, reiterates a Buy rating on the shares with a $10 price target. Aspen University's legacy business performed well in Q4 and is "humming along," Martinuzzi tells investors in a post-earnings research note.
CARS Cars.com
$23.94

-0.37 (-1.52%)

12/07/18
SBSH
12/07/18
INITIATION
Target $70
SBSH
Buy
Citi calls Etsy and Carvana favorites in Specialty Internet
Citi analyst Nicholas Jones initiated coverage of both Etsy (ETSY) and Carvana (CVNA) with Buy ratings and price targets of $70 and $55, respectively. Carvana and Etsy are the analyst's favorites of the Specialty Internet companies.
12/07/18
SBSH
12/07/18
INITIATION
Target $27
SBSH
Neutral
Cars.com initiated with a Neutral at Citi
Citi analyst Nicholas Jones started Cars.com with a Neutral rating and $27 price target.
11/13/18
BTIG
11/13/18
INITIATION
BTIG
Neutral
Cars.com initiated with a Neutral at BTIG
BTIG analyst Marvin Fong initiated Cars.com with a Neutral rating as part of his broader research note titled "Online Automotive Marketplaces: An Industry in Transformation". The analyst notes that the company "has struggled with dealer attrition" and its organic growth has turned negative, but also cites the recent New York Post article which suggests that the company is for sale following an activist involvement. Fong further states that a deal in "low $30s per share" would be feasible, and that the 11-times forward EBITDA valuation multiple on Cars.com is its "main appeal".
08/13/18
DADA
08/13/18
NO CHANGE
Target $12.75
DADA
Neutral
TrueCar price target raised to $12.75 from $10 at DA Davidson
DA Davidson analyst Tom White raised his price target on TrueCar to $12.75 after its Q2 results, saying the quarter showed some "promising tailwinds" with an 8% increase in net franchise revenue and an 8% rise in average monthly unique visitor count. The analyst also keeps his Neutral rating on TrueCar, pointing to a 1.5% decline in company-branded channel units because of "rising competitive ad intensity" from CarGurus (CARG) and Cars.com (CARS). White still believes that TrueCar's 20% growth objective looks "achievable" based on its OEM incentive revenue trends.
TROX Tronox
$7.05

-0.25 (-3.42%)

07/31/18
RHCO
07/31/18
INITIATION
Target $24
RHCO
Buy
Tronox initiated with a Buy at SunTrust
SunTrust analyst James Sheehan initiated Tronox with a Buy rating and a price target of $24 as part of his broader research note suggesting that the titanium dioxide, or TiO2, upcycle is nearing a peak. Despite the pricing pressure, the analyst expects Tronox to become one of the two largest global TiO2 producers pending a merger with Saudi-owned Cristal and contingent on U.S. regulator approval. Sheehan also sees the company benefiting from "tightening mineral sands supply/demand and stable profitability in TiO2 over the next 12 months", allowing the company to generate $100M of synergies in the first year of the acquisition.
09/28/18
JPMS
09/28/18
NO CHANGE
Target $17
JPMS
Overweight
Tronox is 'down, but not out,' says JPMorgan
In a research note titled "Down, but Not Out," JPMorgan analyst Jeffrey Zekauskas keeps an Overweight rating on shares of Tronox. He also lowered his price target for the stock to $17 from $22. The analyst believes Tronox should close its merger with Cristal by the end of 2018 and that the deal "would be quite beneficial to the value" of the company. He expects the company to divest the 245kt of titanium dioxide production in Ashtabula, Ohio owned by Cristal to another party. Tronox offers a 17% free cash flow yield for 2019 and something less than 30% free cash flow yield for 2020, Zekauskas tells investors in a research note.
10/02/18
BMOC
10/02/18
NO CHANGE
Target $13
BMOC
Outperform
Tronox price target lowered to $13 from $28 at BMO Capital
BMO Capital analyst John McNulty lowered his price target on Tronox (TROX) to $13 to adjust for the expiration of the exclusivity window to divest its Ashtabula assets to Venator Materials (VNTR). The analyst expects the company to open up conversations on Ashtabula spinoff, which is required for the Cristal deal to be approved, with a wider range of potential bidders but likely at lower prices. Longer term, McNulty keeps his Outperform rating on Venator, noting that he expects the titanium dioxide "speed bump" to be short lived while the company also works to close on Cristal.
12/10/18
JPMS
12/10/18
NO CHANGE
Target $17
JPMS
Overweight
Tronox has 60%-65% chance of closing Cristal deal, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas thinks the risk/reward balance for Tronox shares is favorable at current levels. It is reasonable for investors to build positions at current prices following the sharp recent pullback, Zekauskas tells investors in a research note titled "Judgment Day." He believes with a a 60%-65% probability that Tronox can close its deal with Cristal and keeps an Overweight rating on the shares with a $17 price target.
CR Crane
$78.23

-0.99 (-1.25%)

12/10/18
BUCK
12/10/18
INITIATION
Target $93
BUCK
Buy
Crane initiated with a Buy at Buckingham
Buckingham analyst Robert Barry initiated Crane with a Buy rating and a price target of $93, citing the "potential for multiple expansion as upside from Crane Currency deal synergies, restructuring benefits, and capital deployment". The analyst notes that his assumption is underpinned by expectations of "generally healthy end markets" and sees the company deploying a portion of its U.S. tax reform savings to "accelerate productivity initiatives." Barry further sees Crane's valuation as reasonable at 7.7-times vs. a historic ex-outlier range of 5.5- to 9.0-times.
07/30/18
UBSW
07/30/18
UPGRADE
Target $100
UBSW
Buy
Crane upgraded to Buy from Neutral at UBS
UBS analyst Damian Karas upgraded Crane to Buy and raised his price target for the shares to $100 from $97. The stock at current valuation levels is not reflecting the company's sustainable annual growth of greater than 3% or strong free cash flow generation in 2019, Karas tells investors in a research note. He views the valuation as "attractive with relatively lower downside risk."
07/30/18
UBSW
07/30/18
UPGRADE
UBSW
Buy
Crane upgraded to Buy from Neutral at UBS
05/25/18
DADA
05/25/18
NO CHANGE
Target $111
DADA
Buy
Crane benefiting from organic growth across its segments, says DA Davidson
DA Davidson analyst Matt Summerville kept his Buy rating and $111 price target on Crane after meeting with its director of investor relations. The analyst says he came away with greater confidence about the company's earnings visibility through 2021 on accretion from Crane Currency, realization of the benefits of U.S. tax reform and expected multi-year growth in its Aerospace/Electronics segment. Summerville adds that Crane's asbestos situation is becoming less of a distraction and that he is hopeful for recovery in Process Valve division.
SFIX Stitch Fix
$25.92

-0.42 (-1.59%)

11/19/18
WOLF
11/19/18
INITIATION
WOLF
Peer Perform
Stitch Fix initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Adrienne Yih initiated Stitch Fix with a Peer Perform saying she wants to see signs of mass consumer adoption before becoming more constructive.
11/14/18
PIPR
11/14/18
NO CHANGE
PIPR
Piper lays out favorite Consumer stocks to own into holiday season
Piper Jaffray analysts led by Erinn Murphy believe the "solid" consumer spending in the first half of the year can continue into the second half with "favorable weather, clean inventories and an extra day between Thanksgiving & Christmas this year serving as catalysts." Ahead of Black Friday, the firm is laying out its favorite Consumer stocks to own into the Holiday. They include G-III Apparel (GIII), Under Armour (UAA), Estee Lauder (EL), PVH Corp. (PVH), Take-Two Interactive (TTWO), Netflix (NFLX), GoDaddy (GDDY) and Ruth's Hospitality (RUTH). Piper analysts are cautious on shares of Stitch Fix (SFIX) and Michaels (MIK).
10/11/18
PIPR
10/11/18
NO CHANGE
Target $23
PIPR
Neutral
Piper cuts Stitch Fix target to $23 after surveying 409 women
Piper Jaffray analyst Erinn Murphy lowered her price target for Stitch Fix to $23 and keeps a Neutral rating on the shares following her firm's Fall 2018 Women's survey. The survey of 409 women indicates 39% aided awareness for Stitch Fix versus 42% awareness of Amazon Prime Wardrobe (AMZN) and 9% for Trunk Club, Murphy tells investors in a research note. She notes that of the 39% of females who were familiar with Stitch Fix, 56% have tried it and "only" 27% state they will still be on the platform in a year. This would imply a churn rate of 73%, Murphy points out. Further, she believes Stitch Fix has already addressed greater than 30% of the customer base to comparable national retail chains.
10/08/18
KEYB
10/08/18
NO CHANGE
Target $45
KEYB
Overweight
Stitch Fix differentiated model can drive multiyear growth, says KeyBanc
KeyBanc analyst Edward Yruma thinks Stitch Fix's differentiated model can drive "attractive" multiyear growth. The analyst points out that his recent management meetings with the company's COO, CFO, and IR helped allay some of his concerns post Q4. Yruma adds that investment cycles are not unusual for growth companies and can provide attractive entry points. He reiterates an Overweight rating and $45 price target on the shares.
CASY Casey's General Stores
$119.64

-1.78 (-1.47%)

09/18/18
NRCS
09/18/18
UPGRADE
Target $150
NRCS
Buy
Casey's General Stores upgraded to Buy from Neutral at Northcoast
Northcoast analyst Chuck Cerankosky upgraded Casey's General Stores to Buy from Neutral with a $150 price target. The analyst said management's plan to enhance earnings growth and shareholder value is well underway as demonstrated by Q1 results. Cerankosky was "very impressed" with the 1.2 cent per gallon improvement in fuel profits, and said the performance highlights the benefits of managing the motor fuel business more intensely. Given strong valuations around recent acquisitions in the convenience story segment, the analyst believes Casy's General Stores' shares are attractive and recommends purchase.
09/18/18
09/18/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Cognizant (CTSH) upgraded to Buy from Hold at HSBC. 2. Casey's General Stores (CASY) upgraded to Buy from Neutral at Northcoast with analyst Chuck Cerankosky saying management's plan to enhance earnings growth and shareholder value is well underway as demonstrated by Q1 results. 3. Occidental Petroleum (OXY) upgraded to Buy from Hold at Edward Jones. 4. Vale (VALE) upgraded to Neutral from Underperform at Exane BNP Paribas. 5. Targa Resources (TRGP) upgraded to Outperform from Market Perform at Wells Fargo with analyst Michael Blum saying with the addition of the Grand Prix pipeline, Targa should have a fully integrated suite of natural gas liquids logistics assets from gathering and processing in the Permian to pipeline to fractionation to liquefied petroleum gas export. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/20/18
BARD
09/20/18
NO CHANGE
Target $2100
BARD
Outperform
Amazon could add $6B in annual revenue with 3,000 stores, says Baird
The reported expansion of Amazon Go convenience stores is an "inevitable step" for Amazon.com (AMZN) to scale local services, retail technology, and customer data, Baird analyst Colin Sebastian tells investors in a research note after Bloomberg reported the company could open 3,000 cashierless stores by 2021. Using Casey's General Stores (CASY) as a comparison, 3,000 Go stores could translate into at least $3.0B-$6.0B and $1.0B-$2.0B of annual revenue and gross profit contribution, respectively, Sebastian adds, citing his estimates. However, the analyst notes that his initial checks also suggest prices at the Chicago Go location are 10%-25% lower than competing convenience stores. Further, the significant technology costs associated with each location could represent a drag on Amazon's profitability and free cash flow as the pace of store build-out ramps, Sebastian says. Nonetheless, he believes a cashierless experience in grocery would represent a "differentiating shopping experience for consumers" as well as a "significant opportunity" to increase Amazon's share in the $800B U.S. grocery market. Sebastian keeps an Outperform rating on Amazon shares with a $2,100 price target. The stock closed yesterday down 1%, or $14.63, to $1,926.42.
11/20/18
JEFF
11/20/18
NO CHANGE
Target $147
JEFF
Buy
Casey's General Stores Q2 results have upside potential, says Jefferies
Jefferies analyst Christopher Mandeville sees upside to Casey's General Stores' fiscal Q2 results on fuel margins as well as continued grocery strength, a record lottery, and spending restraint. The analyst boosted his price target for the shares to $147 from $142 and keeps a Buy rating on the name. He recommends investors continue to own the name.
NX Quanex
$14.05

-0.13 (-0.92%)

12/18/17
WEDB
12/18/17
DOWNGRADE
Target $24
WEDB
Neutral
Quanex downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Jay McCanless downgraded Quanex to Neutral from Outperform, with a $24 price target, as he does not see a new catalyst on the horizon. Further, the analyst believes cost pressures in titanium dioxide and silica may restrain profit margin growth above management's expectations during FY18.
06/08/18
SIDC
06/08/18
DOWNGRADE
SIDC
Neutral
Quanex downgraded to Neutral from Buy at Sidoti
06/08/18
06/08/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Petrobras (PBR) downgraded to Neutral from Buy at UBS with analyst Luiz Carvalho citing reduced visibility on its long-term pricing policy after the company recently reduced prices, which significantly lowered the chances of the company selling its refining assets, keeping it a monopoly, and exposed it to possible interference depending on the government's policy approach and macro conditions. 2. Domino's Pizza (DPZ) downgraded to Hold from Buy at Maxim with analyst Stephen Anderson saying the company's comp performance and market share gains in the U.S., accelerated unit development worldwide, and mostly favorable cost outlook warrant a premium multiple, but believes these positives have been priced into shares. 3. Noble Energy (NBL) downgraded to Hold from Buy at Tudor Pickering. 4. Sientra (SIEN) downgraded to Hold from Buy at Maxim with analyst Anthony Vendetti saying that while he is optimistic on Sientra's long-term prospects, the valuation is significantly ahead of peer averages and the stock price has exceeded his 12-month target. 5. Quanex (NX) downgraded to Neutral from Buy at Sidoti. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CAMP CalAmp
$17.02

-0.23 (-1.33%)

10/28/18
FANA
10/28/18
NO CHANGE
Target $29
FANA
Strong Buy
First Analysis bullish on CalAmp on increased confidence in consistent growth
First Analysis analyst Howard Smith reiterates a Strong Buy rating on CalAmp after meetings with CEO Michael Burdiek increased his conviction that its strong position in wireless IoT and its strategy to enable large enterprises with hardware and, increasingly, recurring services will lead to more consistent growth and a higher-margin profile, which should reward CalAmp shareholders. The analyst has a $29 price target on the shares.
11/26/18
GSCO
11/26/18
INITIATION
GSCO
Neutral
CalAmp initiated with a Neutral at Goldman Sachs
11/26/18
GSCO
11/26/18
INITIATION
Target $20
GSCO
Neutral
CalAmp initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Jerry Revich initiated CalAmp with a Neutral rating and a price target of $20. The analyst says that he is "constructive" on the company's "opportunity to benefit from rising digitization in its core US transportation telematics business" with an added "significant option value" if it can penetrate the global construction equipment market. Revich also warns however that the slowing U.S. truck and stolen vehicle recovery demand could lead to CalAmp missing consensus FY19-FY21 EBITDA estimates by as much as 13%. The analyst expects US truck production to peak in 2019, "driving an organic growth downturn in 2020-21 for new truck telematics."
11/27/18
11/27/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. CVS Health (CVS) initiated with an Overweight at Cantor Fitzgerald. 2. EVO Payments (EVOP) initiated with a Buy at BTIG. 3. Coherent (COHR) initiated with a Buy at Vertical Group. 4. LPL Financial (LPLA) was initiated with a Conviction Buy at Goldman Sachs while CalAmp (CAMP), Stifel Financial (SF), and Raymond James (RJF) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RARX RA Pharmaceuticals
$17.58

1.13 (6.87%)

12/10/18
RBCM
12/10/18
NO CHANGE
RBCM
Outperform
RA Pharmaceuticals could be strategic target for Alexion, says RBC Capital
RBC Capital analyst Kennen MacKay believes RA Pharmaceuticals' (RARX) zilucoplan gMG data "should impress even the skeptics," but he has received questions about why the stock hasn't inflected higher on data that left him "overall highly impressed." He believes the recent run-up of the stock into the data suggests anticipation of a positive result and also thinks the upside has likely been limited by some anticipation for a dilutive financing. Commenting on why the news "isn't more negative" for Alexion (ALXN), MacKay added that he anticipates that Alexion could have strategic interest in an acquisition of RA, with sufficient financial flexibility to pursue a deal, as the latter gets closer to commercialization. MacKay maintains an Outperform rating on RA Pharmaceuticals shares.
12/10/18
JEFF
12/10/18
NO CHANGE
Target $40
JEFF
Buy
RA Pharmaceuticals price target raised to $40 from $22 at Jefferies
Jefferies boosts its price target for RA Pharmaceuticals to a Street-high $40 following this morning's positive top-line results from the company's Phase 2 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis.
12/10/18
PIPR
12/10/18
NO CHANGE
PIPR
Overweight
Piper says RA Pharma data may be competitive to Alexion, but questions remain
After RA Pharmaceuticals (RARX) reported top-line results from its Phase 2 trial of zilucoplan in generalized myasthenia gravis, or gMG, Piper Jaffray analyst Christopher Raymond said the data generally looks more competitive than he would have expected. However, more details on patient background and safety are needed to make a direct comparison to Alexion's (ALXN) Soliris, said Raymond, who thinks RA's program is "worth monitoring." He keeps an Overweight rating on Alexion shares, which are down 1% to $114.18 in early trading.
10/10/18
10/10/18
UPGRADE

Strong Buy
RA Pharmaceuticals upgraded to Strong Buy ahead of Phase 2 data at Raymond James
As previously reported, Raymond James upgraded RA Pharmaceuticals (RARX) to Strong Buy from Outperform with a $28 price target. Analyst Steven Seedhouse expects Phase 2 data for lead subcutaneous C5 inhibitor zilucoplan in generalized myasthenia gravis expected around YE18 to demonstrate a treatment benefit in a mixed refractory/non-refractory patient population and be competitive with Alexion's (ALXN) Soliris. Seedhouse believes a positive Phase 2 readout could be worth $1B in market cap at least and could treat a broader population of patients than Soliris given subcutaneous administration and pricing leverage.
SAEX SAExploration
$3.33

-0.11 (-3.20%)

TODAY'S FREE FLY STORIES

01:45
11/15/19
11/15
01:45
11/15/19
01:45
General news
Asian Market Update: »

Asian Market Update:…

PAYS

Paysign

$11.27

-0.56 (-4.73%)

20:32
11/14/19
11/14
20:32
11/14/19
20:32
Initiation
Paysign initiated at DA Davidson »

Paysign initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 25

    Nov

  • 26

    Nov

LPTX

Leap Therapeutics

$0.57

-0.5922 (-50.83%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25
Downgrade
Leap Therapeutics rating change at Raymond James »

Leap Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$100.07

0.38 (0.38%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25
Upgrade
Fortinet rating change at Credit Suisse »

Fortinet upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 18

    Nov

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

JD

JD.com

$33.57

0.21 (0.63%)

, WVE

Wave Life Sciences

$27.90

-0.07 (-0.25%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JD

JD.com

$33.57

0.21 (0.63%)

WVE

Wave Life Sciences

$27.90

-0.07 (-0.25%)

RYTM

Rhythm Pharmaceuticals

$21.52

0.38 (1.80%)

JCP

J.C. Penney

$1.10

0.01 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 09

    Dec

SBS

Sabesp

$12.21

-0.02 (-0.16%)

20:22
11/14/19
11/14
20:22
11/14/19
20:22
Earnings
Sabesp reports Q3 adjusted EBITDA up 109.8% at BRL3.01B »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

LINX

Linx S.A.

$7.11

-0.8 (-10.11%)

19:16
11/14/19
11/14
19:16
11/14/19
19:16
Recommendations
Linx S.A. analyst commentary at Jefferies »

Linx S.A. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CNP

CenterPoint Energy

$26.68

-1.42 (-5.05%)

19:12
11/14/19
11/14
19:12
11/14/19
19:12
Downgrade
CenterPoint Energy rating change at Credit Suisse »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$309.54

0.46 (0.15%)

19:09
11/14/19
11/14
19:09
11/14/19
19:09
Periodicals
Kudlow says U.S. near trade agreement with China, Reuters says »

White House economic…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$309.54

0.46 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$75.55

-0.54 (-0.71%)

18:41
11/14/19
11/14
18:41
11/14/19
18:41
Hot Stocks
BioMarin CEO: Our products have a very long life cycle »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

OXY

Occidental Petroleum

$37.76

-0.36 (-0.94%)

18:38
11/14/19
11/14
18:38
11/14/19
18:38
Periodicals
Judge rejects Icahn's suit seeking Occidental acquisition records, Reuters says »

A Delaware court judge…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTCH

Farfetch

$7.49

-0.54 (-6.72%)

, DGII

Digi International

$15.10

0.33 (2.23%)

18:35
11/14/19
11/14
18:35
11/14/19
18:35
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

FTCH

Farfetch

$7.49

-0.54 (-6.72%)

DGII

Digi International

$15.10

0.33 (2.23%)

AMAT

Applied Materials

$56.89

-0.24 (-0.42%)

KLIC

Kulicke & Soffa

$25.18

-0.22 (-0.87%)

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

WPM

Wheaton Precious Metals

$26.47

-0.12 (-0.45%)

RDNT

RadNet

$15.92

0.09 (0.57%)

RH

RH

$175.19

1.98 (1.14%)

ACB

Aurora Cannabis

$3.29

-0.25 (-7.06%)

OSMT

Osmotica Pharmaceuticals

$4.00

-0.03 (-0.74%)

GLOB

Globant

$108.99

3.975 (3.79%)

DLB

Dolby

$65.56

-0.14 (-0.21%)

NVDA

Nvidia

$209.88

1.33 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 20

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 13

    Dec

  • 06

    Jan

VIA

Viacom

$25.31

0.175 (0.70%)

, VIAB

Viacom

$22.48

0.44 (2.00%)

18:24
11/14/19
11/14
18:24
11/14/19
18:24
Hot Stocks
Viacom CEO: The road ahead for the company is very exciting »

In an interview on…

VIA

Viacom

$25.31

0.175 (0.70%)

VIAB

Viacom

$22.48

0.44 (2.00%)

CBS

CBS

$37.62

0.78 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 09

    Dec

NVDA

Nvidia

$209.88

1.33 (0.64%)

18:22
11/14/19
11/14
18:22
11/14/19
18:22
Hot Stocks
Breaking Hot Stocks news story on Nvidia »

Nvidia CFO says continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

NVDA

Nvidia

$209.88

1.33 (0.64%)

18:04
11/14/19
11/14
18:04
11/14/19
18:04
Hot Stocks
Nvidia CEO says Q4 will be much stronger driven by AI and inference »

Says computational…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

BABA

Alibaba

$182.69

0.21 (0.12%)

17:50
11/14/19
11/14
17:50
11/14/19
17:50
Syndicate
Alibaba launches Hong Kong IPO »

Alibaba Group Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

17:49
11/14/19
11/14
17:49
11/14/19
17:49
Conference/Events
William Blair SaaS analyst to hold a luncheon meeting »

SaaS Analyst Pfau holds a…

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

17:49
11/14/19
11/14
17:49
11/14/19
17:49
Earnings
Helmerich & Payne sees FY20 CapEx approximately $275M-$300M »

57-62% expected for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

PPG

PPG

$129.82

-0.5 (-0.38%)

, PG

Procter & Gamble

$120.49

-0.15 (-0.12%)

17:49
11/14/19
11/14
17:49
11/14/19
17:49
Hot Stocks
Trian Fund exits PPG, cuts Wendy's in Q3 »

Nelson Peltz' Trian…

PPG

PPG

$129.82

-0.5 (-0.38%)

PG

Procter & Gamble

$120.49

-0.15 (-0.12%)

MDLZ

Mondelez

$52.90

0.2 (0.38%)

LM

Legg Mason

$38.60

-0.22 (-0.57%)

GE

General Electric

$11.30

-0.01 (-0.09%)

WEN

Wendy's

$20.90

-0.01 (-0.05%)

BK

BNY Mellon

$48.42

0.07 (0.14%)

SYY

Sysco

$81.51

0.27 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 02

    Dec

  • 11

    Dec

  • 16

    Jan

  • 29

    Jan

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

17:48
11/14/19
11/14
17:48
11/14/19
17:48
Earnings
Helmerich & Payne reports Q4 cont ops EPS 38c, consensus 23c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

17:47
11/14/19
11/14
17:47
11/14/19
17:47
Conference/Events
DA Davidson software analysts to hold a dinner meeting »

Analysts host a Security…

MDCO

The Medicines Co.

$50.89

-1.905 (-3.61%)

17:46
11/14/19
11/14
17:46
11/14/19
17:46
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

NVDA

Nvidia

$209.88

1.33 (0.64%)

17:44
11/14/19
11/14
17:44
11/14/19
17:44
Hot Stocks
Nvidia CFO says Q3 decline in automotive revenue driven by one-time item »

Says AI cockbit business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

CPE

Callon Petroleum

$4.20

-0.265 (-5.94%)

, PSDO

Presidio

$16.56

-0.02 (-0.12%)

17:44
11/14/19
11/14
17:44
11/14/19
17:44
Hot Stocks
Paulson adds Callon Petroleum, lowers stake in Lyft in Q3 »

John Paulson's…

CPE

Callon Petroleum

$4.20

-0.265 (-5.94%)

PSDO

Presidio

$16.56

-0.02 (-0.12%)

OSG

Overseas Shipholding

$1.84

0.045 (2.51%)

STC

Stewart

$43.10

0.11 (0.26%)

AGN

Allergan

$182.47

0.91 (0.50%)

HZNP

Horizon Pharma

$29.82

-0.48 (-1.58%)

ONCE

Spark Therapeutics

$110.78

-0.65 (-0.58%)

MYL

Mylan

$17.26

-0.01 (-0.06%)

S

Sprint

$5.86

-0.21 (-3.46%)

LYFT

Lyft

$41.90

-1.39 (-3.21%)

TMUS

T-Mobile

$76.87

-1.15 (-1.47%)

PCG

PG&E

$6.70

-0.19 (-2.76%)

WCG

WellCare

$301.86

-2.56 (-0.84%)

TSU

Tim Participacoes

$15.53

0.44 (2.92%)

GLD

SPDR Gold Shares

$138.57

0.59 (0.43%)

BHC

Bausch Health

$27.77

0.38 (1.39%)

CELG

Celgene

$110.03

-0.42 (-0.38%)

DISCK

Discovery Inc.

$28.04

0.12 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 07

    Jan

  • 25

    Mar

  • 04

    Apr

17:41
11/14/19
11/14
17:41
11/14/19
17:41
Conference/Events
BTIG energy analysts to hold a luncheon »

Energy Analysts host…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.